Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “LNTH-2403 administered once every 8 weeks, with the potential to explore other dosing schedules based on observed radiation dosimetry and PK parameters and safety and tolerability data.”In the company’s words, NCT07357519 on ClinicalTrials.gov
- Tested for
- Relapsed / Refractory Osteosarcoma
- Main trialPhase 1/2
- “This is a multi-center, non-randomized, open-label, dosimetry and dose-escalation, cohort-expansion study of LNTH-2403 administered to subjects with relapsed / refractory (R/R) osteosarcoma. This study consists of 2 phases: (1) a dosimetry and dose escalation phase; and (2) a cohort expansion phase.”In the company’s words, NCT07357519 on ClinicalTrials.gov
Other drugs for Relapsed / Refractory Osteosarcoma
- HS-20093Hansoh · Phase 2
- KC1036Beijing Konruns Pharmaceutical Co., Ltd. · Phase 2
- EntrectinibRoche · Phase 1/2
- VactosertibMedPacto, Inc. · Phase 1/2
- LurbinectedinJazz Pharmaceuticals · Phase 1/2
- SOT106SOTIO Biotech a.s. · Phase 1/2
Coming up1
- Aug 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Aug 2027 | Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026